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ABSTRACT 
 
The association of interferon therapy with hemolytic uremic syndrome in patients with 
chronic myeloid leukemia (CML) has beeen reported infrequently. The pathogenesis of the 
renal lesion in such cases remains unclear. We report the case of a patient with chronic 
myeloid leukemia who developed nephrotic syndrome and renal failure  while being treated 
with hydroxyurea and interferon- α. Renal biopsy showed features of chronic thrombotic 
microangiopathy. The discontinuation of interferon- α, and a prompt institution of 
plasmapheresis and steroids resulted in improvement of the nephrotic syndrome and renal 
function. These findings suggest that long-term interferon- α therapy can induce thrombotic 
microangiopathy and hemolytic uremic syndrome in patients with chronic myeloid leukemia. 
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INTRODUCTION  
 
 
Therapy for chronic myeloid leukemia (CML) constists of cytoreduction (typically 
with hydroxyurea) and interferon-α: only a minority undergo bone marrow transplantation. 
Only, a few reports of renal thrombotic microangiopathy has been described in patients with 
CML. In almost all cases these patients were receiving interferon-α (1-6). The interferons are 
a family of glicoproteins with antiviral, antitumor and immunomodulatory activities. 
Interferon-α is used particularly in the treatment of chronic myeloid leukemia, and other 
haematological malignanices as well as in hepatitis C. Various adverse effects associated with 
interferon-α have been reported previously, including cardiac and renal dysfunction (7). In 
patients with chronic hepatitis C, interferon-α therapy is rarely associated with renal side 
effects (8). In patients receiving high doses of interferon-α for malignancy, a wide range of 
renal side effects have been reported, including proteinuria, acute interstital nephrititis and 
membranoproliferative glomerulonepfritis (9-12). In some cases, the discontinuation of 
treatment led to the recovery of renal function, but irreversible renal failure may occur (4-6). 
Many authors have observed various renal toxicities with interferon-α therapy, but the 
incidence of renal complications remains unknown and the causal link between interferon-α 
and thrombotic microangiopathy is still underappreciated. 
We described a case of haemolytic uremic syndrome that occured in a patient with CML 
receiving interferon-α and hypotheses regarding the potential  mechanisms underlying this 
association are discussed. 
 
 
CASE REPORT 
 
 
A 45-year-old man was admitted in July 2001 because of increased leukocytes and 
plateletes. Previous medical history was unremarkable. Physical examination  showed 
hepatosplenomegalia. The peripheral blood leukocytes count was 43x109/L, Hb 111 g/L, 
platelets 1209x109, serum creatinine was 88µmol/L, urinalysis was normal. The bone marrow 
biopsy was diagnostic of CML and the presence of th Philadelphia chromosome.Treatment 
included hydroxyurea (50mg/kg/day) and interferon-α (Roferon) 9x106 IU 
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subcutaneously/day and allopurinol 100mg/day. One year later his peripheral leukocytes 
count had decreased to 18.1x109, and platelets to 457x109. Hepatosplenomegalia had 
regressed. In August the patient was referred to Nephrology department for edema and a 
recently discovered impairment of renal function (serum creatinine 450µmol/L). 
On admission he was pale, had high blood pressure (190/120 mmHg), bibasal  lung crackeles, 
hepatosplenomegaly, and marked lower limb edema. Urinary dipstick showed protein ++, 
trace red cells, microscopy showed a few granular casts only. Ultrasound showed normal 
sized kidnyes with echogenic cortex. Severe anemia with a hemoglobin level of 49 g/dl was 
present, hematocrit was 0.33, mean corpuscular volume 0,93fl and reticulocyte count  was  
1,2%. He had the following results: WBC 4.9x109 platelets  128x109, total bilirubin 17 
µmol/L (reference range 3.4-20.5 µmol/L µmol/L)  lactate dehidrogenase (LDH) 2845 U/L 
(reference range 170-430 U/L), Coombs test-indirect was positive, normal liver enzymes, 
creatinine 450 µmol/L (reference range 64-120 µmol/L). The following tests were negative or 
normal: antinuclear antibody (ANA), hepatitis B, surface antigen (HbsAg) hepatitis B core 
antibody (HbcAb) human immunodeficiency virus antibody (HIV), protrombin time (PT) 
partial thromboplastin time (PTT), serum fibrinogen, fibrin split products and serum 
haptoglobin. Serum C3 were depressed at 0,57 (reference range, 0.9-1.8g/L) serum C4 was 
0.12g/L (reference range 0.1-to 4.0 g/L). A peripheral blood smear revealed moderate 
schistocytosis. Serum protein electrophoresis was normal, proteinuria was 16.2 g/day (normal 
value <0.2g/day). Bone marrow biopsy revealead a CML. Fundoscopy detected  a stage II 
retinopathy 
 Percutaneous renal biopsy  disclosed typical changes of thrombotic microangiopathy: 
by light microscopy all glomeruli (20 glomeruli) were globally enlarged. The remainder 
showed increased mesangial matrix cells and pronounced thickening of peripheral capilary 
loops (Figure 1). Diffuse subendothelial swellings of the glomerular capillary walls coexisted 
with focal thrombi of the capillay lumen and of the arterioles whose intima was extensively 
swollen.  
The latter finding was associated with marked «double contour» formation  (duplication of the 
basement membrane) and with interposition of cell elements within the thickened capillary 
walls. Many of the glomerular capillaries were occluded by the thickened walls and swollen 
endothelial cells. Significant interstitial  fibrosis was also present. The smaller arteries and 
arterioles showed marked fibrocellular proliferation with myxoid change and focal hyline 
deposition, often resulting in significant narrowing of vessel lumen. Immunofluorescence 
microscopy showed large granular deposits of immunoglobulin M (IgM) and fibrin. Electron 
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microscopy showed extensive capillary wall changes with degenerative change of the 
endothelium and loss of fenestrae; there was widening of the subendothelium space by 
electron-lucent material and by cellular projections and formation of the new basement 
membrane under displaced endothelial cells (Figure 2).  The light and electron microscopy 
findings  were highly suggestive of thrombotic microangiopathy. 
A diagnosis of HUS was made and the patient was started on daily plasmapheresis (7 days). 
The patient was also given corticosteroids, aspirin and antihypertensivs. Renal function 
improved and stabilized with serum creatinine of 200µmol/l. His Hb incresed to 100g/L. 
Interferon-α was withdrown and oral hydroxyurea was continued for menagement of the 
CML. The patient was seen for his outpatient control one and two months latter. His renal 
function was improving (creatinine 170µmol/l) and CML in stable phase.   
 
 
     DISCUSSION 
 
 The mechanisms by which interferon-α therapy may initiate HUS are unknwn, but 
several mechanisms are possible. Intereferon- α  has been shown to increase leukocytes 
adherence to vascular endothelium, and this may initiate endothelial cell damage and 
subsequent release of large multimers of the von Willebrand factor, causing endothelial cell 
swelling, patelet aggregation and intraluminal microthrombi formation. Unusually large 
multimers of von Willebrand factor are probalby cleaved by metalloprotease-ADAMTS 13 
directly on the surface of endothelial cells. Some of the patients with hemolytic-uremic 
syndrome have a deficiency or defect of complement factor H (13). It will be useful to 
measure antibodies of ADMTS 13 and antibodies of H factor, wich could better illustrate the 
mechanism of HUS in our patient, but we could not measure it. Some autors suggested that 
activated leukocytes and/or their products, such as TNF, IFN, IL-1 and free radicals can 
participate in tissue injury and endothelial  cell damage with the resulting deleterius effects 
(14). Indeed, in an experimental model of HUS a central role for leukocytes  or leukocyte 
products had been suggested and in vivo neutralisation of TNF or IFN  with a specific 
antiserum protected  mice from an HUS-like reaction (15). Therefore, IFN-induced free 
radicals production by activated phagocytes may result in the pathogenesis of HUS. Another 
report showed incresed IFN production in two patients with HUS associated with adenovirus 
infection and a possible nephrotoxic role from elevated IFN levels was speculated (16). 
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Possible nephrotoxic effects of IFN have been previously reported. Exogenous interferons 
could cause similar effects. 
The possible role of interferon-α  inducing this toxic effect is increasingly suspected as 
more case reports are described. In our patient, the clinical presentation and laboratory 
findings are consistent with the diagnosis of thrombotic mycroangiopathy and renal 
dysfunction and the presence of schistocytes in the blood smear were detected. Platelets in our 
patient were slightly decreased (platelets  128x109).  
Because renal failure was predominant feature at presentation of our patient this 
disorder was considered to be the haemolytic-uremic syndrome. The clinical distinction 
between thrombotic thrombocytopenic purpura and haemolytic-uremic syndrome is not 
always clear (14). Treatment with interferon-α  was probably the only factor involved in the 
development of HUS. No other known causes could be suspected in our patient.  
The subsidence of HUS after the cessation of interferon therapy strongly supports the 
view that interferon caused HUS in our patient. 
HUS has already been reported during tretment with a number of cytotoxic agents 
(mitomycin, methyl-carmustin, bleomycin, daunomycin, cisplatin, and deoxycoformycin) but 
has never to date been described with hydroxyurea, suggesting a role for interferon- α. 
The association of interferon-α therapy with hemolytic uremic syndrome and 
thrombotic thrombocytopenic purpura has been reported infequently. Only sporadic cases of  
HUS have been reported in association with interferon tretment in CML (1-6). 
HUS is a rare side effect that occurs in only small subgroup of patients given 
interferon- α for CML. There is a possible genetical predisposition in these patients. Several 
studies have demonstrated genetic predisposition in non-shigatoxin-associated hemolytic 
uremic syndrome, involving regulatory proteins of the complement alternative pathway: 
factor H and membrane co-factor protein (CD46) (17). 
The associaton of malignant disorders and cancer chemotherapeutic agents with 
hemolytic uremic syndrome (HUS) and thrombotic microangiopathy (TTP) has been 
previously described (18, 19). Most cases occur in patients with adenocarcinomas, gastric 
adenocarcinoma being the most common, but also with small lung carcinoma, squamous 
carcinoma and Hodgkin disease. CML has been uncommonly associated with microangiopatic 
disorders (20, 21, 22). In HUS,  renal endothelial cell injury, with endothelial cell swelling 
and the resulting narrrowing of the glomerular capillary lumen, is belived to be the initiating 
event. HUS is commonly preceded by bloody diarrhea caused by infectious orgnanisms, such 
as Shigella dysenteriae  or E. coli. The toxins secreted by these organisms, are capable of 
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binding  the predominanat membrane globotrisyl ceramide (Gb3). Gb3 is expressed on the 
membrane of renal endothelial cells and other endothelial cells. Other agents can up-regulate 
Gb3 expression on the endothelial cells and therefore potentiate the effects of the toxins. 
These include the cytokines interleukin (IL-1) or alfa or beta tumor necrosis factor (TNF)-alfa 
or beta (18). 
The pathogenesis of HUS in Shigella infection is similar to HUS caused with 
interferon- α. The damage of glomerular endothelial cells by Shiga toxin 1 and 2 is 
potentiated by the monocytes and neutrophils that invade glomeruli in response to the secreted 
interleukin-8 and the production of monocytes chemoattractant protein 1 by renal cells. 
Interleukin-8-activated neutrophils release oxygen-derived free radicals, hydrogen peroxide, 
elastase and other protease that potentiate the damage to the kidneys. In fact, neutrophilia 
increases the likelihood of irreversible renal injury. The death and desquamation of 
endothelial cells in the kidneys may also promote, by means of glycoproteins Ibα, the 
adhesion of platelets to unusually large multimers of von Willibrand factor in the 
subendothelium. Subsequent binding of fibrinogen to activated platelet glycoprotein IIb/IIIa 
complexes induces the aggregation of platelets under conditions of  high flow as occur in the 
glomerular microcirculation 
In summary, HUS is a rare side effect of interferon-α therapy in patients with CML. 
The mechanisms contributing to its pathogenesis are poorly understood but interferon-α can 
through modulatory effects on endothelial receptors make these cells more susceptible to the 
effects of bacteria toxins. They may also mediate free radical production by activating 
phagocytic cells and as a result cause endothelial cell injury. The release of platelet-
aggregating agents from the damaged endothelial cells is probably the event resulting in 
intraluminal thrombus formation and organ damage, as seen in HUS. This rare but definite 
complication of interferon-α therapy should be recognised early when clinical and laboratory 
findings are suggestive so interferon-α therapy can be discontinuated immediately and 
appropriate therapeutic measures can be initiated. 
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Figure 1. Haemolytic-uremic syndrome. A large glomerulus with inconscpicous mesangium 
because of mesangiolysis. Capillaries are dilated, some filled with thrombi and some have 
splitet, double contoured basement membranes. P.A.S. method. 400x 
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Figure 2. An ultrastructural detail of a glomerulus. One can see the detachment of endothelial 
cells from GBM with formation of the clear space filled with some fluffy material. Uranyl-
acetate and lead cytrate. 24500 
x. 
